期刊
CALCIFIED TISSUE INTERNATIONAL
卷 111, 期 1, 页码 102-106出版社
SPRINGER
DOI: 10.1007/s00223-022-00969-x
关键词
Calcitriol; Phosphate; FGF23 resistance; Hypercalciuria; GALNT3 mutation
资金
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq
- Comissao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
- Post-Graduation Program of UNIFESP
Hyperphosphatemic familial tumor calcinosis (HFTC) is a rare disease characterized by high levels of phosphate in the blood and deposition of calcium and phosphorus crystals. This case report describes a 50-year-old woman diagnosed with HFTC, who had a homozygous variant in the GALNT3 gene. Despite treatment with acetazolamide, sevelamer, and a phosphorus-restricted diet, her phosphatemia remained high and calcifications continued to progress. The use of teriparatide (TPTD) showed some effectiveness in reducing phosphatemia, but also led to increased calciuria.
Hyperphosphatemic familial tumor calcinosis (HFTC) is a rare disease characterized by hyperphosphatemia and calcium and phosphorus crystal deposition. It occurs due to the loss of function of FGF23. Herein, we report a case of a 50-year-old woman diagnosed with HFTC (homozygous variant in the GALNT3 gene, c.803_804 C insertion) with a history of ectopic calcifications in the past 30 years. Laboratory tests on admission were as follows: phosphate (P) 7.1 mg/dL (Normal range (NR) 2.5-4.5 mg/dL), FGF23 c-terminal 2050 RU/mL (NR < 150 RU/mL), and intact FGF23 (iFGF23) 18.93 pg/mL (NR 12.0-69.0 pg/mL). Treatment with acetazolamide, sevelamer, and a phosphorus-restricted diet was started, but phosphatemia remained high and calcifications continued to progress. In an attempt to further decrease P, a 36-day cycle of teriparatide (TPTD) 20 mcg twice daily was added, decreasing P from 6.2 to 5.2 mg/dL and increasing the 1.25(OH)(2) vitamin D by 34.2%. As urinalysis was not feasible at the end of the 36-day cycle, a second cycle was performed for another 28 days, producing a similar decrease in P (from 6.4 to 5.5 mg/mL) and an evident decrease in the rate of tubular reabsorption of P (from 97.2 to 85.3%), however, accompanied by a worrying increase in calciuria. The use of TPTD 20 mcg twice daily in a patient with genetic resistance to FGF23 (HFTC) was associated with consistent increase in phosphaturia and reduction in phosphatemia, in addition to an increase in calcitriol. The resulting hypercalciuria precludes the therapeutic use of TPTD in HFTC and suggests an important role of FGF23, not only in phosphate homeostasis but also in avoiding any excess of calcitriol.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据